Chemomab Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A merger was announced to advance nebokitug, a dual-acting antibody for RA, leveraging Scipher's AI-driven precision medicine platforms and clinical infrastructure. A phase II RA trial using biomarker-driven patient selection is planned, with key milestones through 2028.
-
The merger creates a precision medicine leader in RA by combining AI-driven diagnostics with a novel anti-CCL24 antibody, supported by $30M in new funding and a de-risked clinical strategy. The combined company targets a major unmet need in RA, with Phase II data expected in 2028.
-
Nebokitug is advancing to phase III for PSC after strong phase II results, with plans to focus on moderate to advanced patients and pursue partnerships for commercialization. The drug also shows promise in systemic sclerosis, targeting a combined market opportunity exceeding $2.5 billion.
Fiscal Year 2025
-
Positive phase II results for nebokitug in PSC showed strong anti-inflammatory and anti-fibrotic effects, with FDA alignment for a single pivotal phase III study. The drug is positioned as a potential first-in-class, disease-modifying therapy with significant commercial potential.
-
CM-101 (Nebokitug) achieved clinical proof of concept in PSC, with significant efficacy and safety in Phase II, and is advancing to a global Phase III trial. Two major milestones—FDA feedback and open-label extension data—are expected in Q1 2025, with strong investor and partner interest.
Fiscal Year 2024
-
The phase II SPRING trial of CM-101 in PSC met its primary safety endpoint and showed significant improvements in liver stiffness, ELF score, pruritus, and other key biomarkers, especially in patients with moderate to advanced disease. Plans are underway for a phase III trial and further strategic development.